Registration

OMB No. 0925-0740  
Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Please complete this form to register for the Survivorship Issues for Individuals Living with Advanced and Metastatic Cancers: Stakeholder Meeting. An asterisk (\*) indicates required information.

**Meeting Information**

The meeting will run from approximately TBD to TBD p.m. ET on May 10th and TBD to TBD ET on May 11th.

We encourage those wishing to participate to register by **Friday, May 7, 2021**. There is no fee to attend the Survivorship Issues for Individuals Living with Advanced and Metastatic Cancers: Stakeholder Meeting. Registrants will receive the meeting login information prior to the meeting.

\* First Name

First Name is required.

\* Last Name

Last Name is required. First Name is required.

\* Title



\* Degree



\* Email

Email is required. Email format is not correct, please ensure your entry is accurate.

\* Institute/Organization

Email is required. Email format is not correct, please ensure your entry is accurate.

\*Professional Role (select the one most relevant for this conference/meeting)

clinician

researcher

patient/survivor

advocate

caregiver

NCORP Program is required.

\*If Other, explain



I would like to opt in to receiving future information from NCI on survivorship for individuals living with advanced and metastatic cancer.